Therapeutic Effect of Compression Stockings Versus no Compression on Isolated Superficial Vein Thrombosis of the Legs: A Randomized Clinical Trial  by Boehler, K. et al.
Therapeutic Effect of Compression Stockings Versus no Compression on
Isolated Superﬁcial Vein Thrombosis of the Legs: A Randomized Clinical Trial
K. Boehler *, H. Kittler, S. Stolkovich, S. Tzaneva
Department of Dermatology, Division of General Dermatology, Medical University Vienna, Waehringer Guertel 18e20, A-1090 Vienna, Austria* Co
E-ma
1078
Surgery
http:WHAT THIS PAPER ADDS
To the authors’ knowledge, this is the ﬁrst randomized controlled trial in which the therapeutic effect of
compression stockings on isolated superﬁcial venous thrombosis of the legs has been studied. The results of the
study showed no additional beneﬁt of wearing compression stockings versus no compression after 3 weeks with
respect to resolution of pain, the consumption of analgesics, thrombus regression, and improvement in quality
of life. However, after 1 week there was signiﬁcantly faster thrombus regression stimulated by compression
stockings.Objective/Background: Leg compression is considered basic treatment for superﬁcial vein thrombosis (SVT),
although scientiﬁc proof for its efﬁcacy is lacking. The aim of the study was to evaluate the therapeutic effect of
compression stockings on isolated SVT of the legs.
Methods: This was a single-center randomized controlled trial. Eighty patients with isolated SVT of the legs were
instructed to wear compression stockings (23e32 mmHg) (CG) or no compression (NCG) for 3 weeks. All patients
received low molecular weight heparin (LMWH) at prophylactic dosage. Non-steroidal anti-inﬂammatory drugs
(NSAIDs) were allowed. The primary outcome variable was the reduction of pain as assessed by a visual analog
scale (VAS) and the Lowenberg test. Secondary outcomes were the consumption of analgesics, thrombus length,
skin erythema, D-dimer, and quality of life (QoL).
Results: Seventy-three patients completed the study. Clinical symptoms and QoL signiﬁcantly improved from
baseline to day 21 in both groups (p < .001 for VAS, Lowenberg test, thrombus length, and erythema; p < .006
for QoL), and consumption of analgesics and D-dimer signiﬁcantly decreased (p < .001). There was no signiﬁcant
difference between the groups for all tested variables. At day 7, patients in the CG revealed a signiﬁcantly faster
thrombus regression (p ¼ .02).
Conclusion: Adding compression stockings for 3 weeks to LMWH and NSAIDs does not bring signiﬁcant additional
beneﬁt in the treatment of isolated SVT. When worn for 1 week, compression stockings stimulate signiﬁcantly
faster thrombus regression.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Superﬁcial vein thrombosis (SVT) of the legs is a common
clinical condition primarily in patients with varicose veins.
Symptoms include localized pain, inﬂammation, and tender
hardening of the affected vein in connection with thrombus
formation.1 As long as diagnosis was solely based on clinical
presentation, SVT was considered a benign disease. Sys-
tematic duplex sonography has changed this perception and
made it clear that up to 25% of patients also have venous
thromboembolism (VTE) at ﬁrst presentation.2 Treatment
aims are to relieve local symptoms and to prevent VTE
events and thrombus extension. Several randomizedrresponding author.
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//dx.doi.org/10.1016/j.ejvs.2014.06.047controlled trials have evaluated the relative efﬁcacy and
safety of various drug treatment strategies.3e8 Fondapar-
inux given for 45 days at a prophylactic dose was shown to
be highly effective in preventing thromboembolism com-
plications and symptomatic recurrences.4 In an earlier trial,
high- and low-dose low molecular weight heparin (LMWH)
were found to be equally effective in the treatment of SVT5;
more recently a study showed that an intermediate dose of
LMWH for 30 days was superior to a prophylactic dose and
shorter treatment periods.6 In addition, it was demon-
strated that non-steroidal anti-inﬂammatory drugs (NSAIDs)
are equally as effective as LMWH in decreasing local pain
but inferior in preventing thrombus progression and VTE.7,8
Leg compression and mobilization are considered basic
treatment interventions for SVT.1,9 However, the use of
compression is more or less based on subjective experience,
while scientiﬁc evidence for its efﬁcacy is lacking. A number
466 K. Boehler et al.of studies mention compression stockings as an adjunct to
systemic treatment but without evaluating its effect on the
disease process.4,6,7 Only one uncontrolled trial has inves-
tigated the effect of ﬁxed compression bandages on SVT.
This study reported improvement of clinical symptoms in
93% of patients.10
The aim of the present study was to evaluate the efﬁcacy
of compression stockings (23e32 mmHg) in alleviating
clinical symptoms associated with isolated SVT of the legs.
Our hypothesis was that compression is superior to no
compression in reducing disease-related clinical symptoms
and improving quality of life (QoL).
MATERIALS AND METHODS
Study design
This was a prospective randomized controlled open-label
single-center clinical trial performed at the Department of
Dermatology, Medical University of Vienna, Austria from
December 2009 to November 2013 (ClinicalTrials.gov Iden-
tiﬁer: NCTO1976637). The study was conducted according to
the ethical principles stated in the Declaration of Helsinki,
and the local ethical committee approved the protocol.Patients
Outpatients with clinical symptoms (localized redness,
swelling, induration) < 7 days suggestive of SVT of varicose
tributaries with or without extension into the great
saphenous vein (GSV) or small saphenous vein (SSV) trunk
were eligible for the study when SVT was conﬁrmed by
compression ultrasonography (CUS). Additional inclusion
criteria were age >18 years and thrombus length >5 cm.
Exclusion criteria were SVT of the GSV or SSV within 2 cm of
the sapheno-femoral or sapheno-popliteal junction, CUS-
documented proximal or distal deep vein thrombosis
(DVT), SVT secondary to sclerotherapy, thrombophilia,
active cancer, peripheral arterial occlusive disease, immo-
bility, and leg conﬁgurations not covered by readymade
stockings. All patients provided written informed consent.Randomization and intervention
The randomization procedure was performed in a 1:1 ratio
in blocks of 20 with closed envelopes, with the investigators
not being aware of the sequence within the envelopes.
Patients were allocated to two treatment groups: a
compression group (CG) and a no compression group (NCG).
The CG patients wore ready-made, thigh-length compres-
sion stockings, class II (23e32 mmHg; Venotrain, Bauer-
feind, Zeulenroda, Germany), during the day for 3 weeks.
The NCG patients wore no compression.
Compression stockings were selected using a digital
photogrammetry program (Image 3D, Bauerfeind, Zeu-
lenroda, Germany), which facilitates precise contact-free,
three-dimensional measurement of the leg.
All patients received enoxaparin at a prophylactic dose of
40 mg once daily for 21 days. Additional intake of NSAIDs
(mefenaminacid, diclofenac, and dexibuprofen) was allowedaccording to the patients’ individual perception of pain.
Application of anti-inﬂammatory or thrombolytic ointments
was not allowed.
Study procedures
Clinical examination, including evaluation of pain, erythema
measurements, and record of NSAID consumption, as well
as CUS of the superﬁcial venous system were performed at
baseline and at day 7, 14, and 21.
CUS involved the entire superﬁcial venous system of the
affected leg from the groin to the ankle. The compressibility
of the veins was assessed in the transverse plane with B-
mode. Failure to compress the lumen with the probe was
the sole criterion for the diagnosis of vein thrombosis. A
distance of >2 cm of the thrombus head from the sapheno-
femoral or sapheno-popliteal junction was conﬁrmed. For
assessment of the deep veins the common femoral, deep
femoral and femoral, popliteal, posterior tibial, ﬁbular, and
muscular veins were scanned in the same manner at
baseline and on day 21.
Platelet counts were done at baseline, on day 7, and 14,
and D-dimer measurements at baseline and on day 21. All
patients completed QoL questionnaires (SF-36) prior to
treatment and on day 21.
Outcome assessment
The primary outcome measure for effectiveness was a
composite of spontaneous and induced pain assessed dur-
ing the 3-week follow-up. Secondary outcome measures
were the amount of analgesics consumed, skin erythema,
thrombus length, D-dimer, and QoL. The main safety out-
comes were symptomatic or asymptomatic DVT and
heparin-induced thrombocytopenia (HIT).
Spontaneous pain was assessed using an 11-point nu-
merical rating scale (the visual analog scale [VAS]), in which
0 signiﬁes no pain and 10 the worst possible pain. Induced
pain was assessed with a modiﬁed Lowenberg test.11
Pressure was applied with a cuff at the area of the SVT
and the respective area of the contralateral leg. The value at
which the patient perceived pain was recorded. The abso-
lute value of the difference between the affected and the
healthy leg was used for analysis.
The consumption of analgesics was measured by count-
ing the number of tablets taken to control pain.
Skin erythema was outlined on the skin and documented
with a digital camera (Nikon Coolpix p80; Nikon, Tokyo, Japan).
The affected area (cm2)was calculated usingdigital planimetry.
Thrombus length was evaluated by duplex sonography.
The most proximal and distal point of the thrombus were
located with the transducer probe and marked on the skin.
For calculation, the distance between these points was
measured with a ruler (cm).
The SF-36, including eight domain scores for physical and
mental functioning, was calculated following standardized
procedure.12
DVT was deﬁned as a new incompressible segment in the
deep venous system.
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baseline.Statistical analysis
Based on prior observations, it was estimated that the SD of
the VAS was 10 and that a clinical meaningful difference of
the VAS was between 7 and 10, which corresponds to a
standardized difference of 0.7 and 1, respectively.13 To
detect a standardized difference of 0.7 with a power of 80%
and a ¼ .05, a sample size of 65 patients was needed.
Data in both groups were analyzed according to the
intention-to-treat principle. Unless otherwise speciﬁed,
continuous data are given as mean and the SD. A repeated
measures analysis of variance was used to compare the
outcome variables at different time points between treat-
ment groups. All given p-values are two-tailed and a p-value
<.05 indicates statistical signiﬁcance. SPSS 20.0 (version
20.0) was used for all statistical analyses (IBM, Armonk, NY,
USA).Figure 1. Trial proﬁle. Note. DVT ¼ deep vein thromboRESULTS
One hundred and forty-seven patients were screened for
study participation and 80 underwent randomization
(CG ¼ 39; NCG ¼ 41) (Fig. 1). Thirty-ﬁve patients in the CG
(90%) and 38 patients in the NCG (93%) completed the
study protocol, and their data were analyzed over the
whole observation period. Patient demographics are given
in Table 1. There were no signiﬁcant differences in baseline
characteristics between the two treatment groups.Primary and secondary outcomes
The results of primary and secondary outcomes are detailed
in Table 2 and Figs. 2e4.
Pain. Both treatment groups showed a signiﬁcant reduction
of spontaneous and induced pain from baseline to day 21
(Figs. 2 and 3). This was documented by decreasing VAS
scores from a mean of 5.1 (SD 2.5) to 0.8 (SD 1.4) in the CG,
and 4.4 (SD 2.4) to 0.9 (SD 2.2) in the NCG (p< .001 for bothsis; NSAID ¼ non-steroidal anti-inﬂammatory drug.
Table 1. Baseline demographic and clinical characteristics of study
patients with full observation.
Features Compression
(n ¼ 35)
No compression
(n ¼ 38)
Age (y) 56.3 (13.2) 60.3 (14.8)
Female sex (n) 23 (65.7%) 30 (78.9%)
Visual analog scale
(cm)
5.2 (2.5) 4.4 (2.4)
Lowenberg test
(mmHg)
49.7 (56.1) 51.8 (38.8)
Thrombus length
(cm)
24.6 (15.2) 18.9 (11.5)
Skin erythema (cm2) 62.8 (62.8) 69.3 (62.3)
D-Dimer (mg/mL) 1.1 (1.0) 1.2 (0.9)
SF-36
Physical score 41.8 (8.1) 39.5 (10.2)
Mental score 47.7 (11.1) 50.8 (10.0)
Note. Values are mean (SD) unless otherwise stated.
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468 K. Boehler et al.groups).The Lowenberg test decreased from49.7 (SD 56.1) to
7.1 (SD 21.9) in the CG, and 51.8 (SD 38.8) to 8.8 (SD 26.2) in
the NCG (p< .001 for both groups). No statistically signiﬁcant
difference in pain reduction was found between the two
groups (VAS p ¼ .33; Lowenberg p ¼ .810).
NSAIDs. Consumption of analgesics signiﬁcantly decreased
during the observation period from mean 4 (SD 5) to 2 (SD
3) in the CG (p < .001), and from 6 (SD 6) to 2 (SD 4) in the
NCG (p < .001). Overall, comparison between groups did
not show a statistically signiﬁcant difference in NSAID
consumption after 3 weeks (p ¼ .600).
Thrombus length. Mean thrombus length signiﬁcantly
decreased from baseline to day 21 from 24.6 (SD 15.2) to
11.8 cm (SD 14.4) in the CG, and from 18.9 (SD 11.5) to
12.9 cm (SD 10.9) in the NCG (p < .001 for both groups)
(Fig. 4). A signiﬁcantly faster thrombus regression noted in
the CG at day 7 (p ¼ .020) disappeared at day 14. Overall,
the rate of improvement in thrombus length at day 21 was
similar in the two study groups (p ¼ .070).
Erythema. Erythema signiﬁcantly improved during the
observation period from a mean of 62.8 (SD 62.8) to
13.9 cm2 (SD 23.5) in the CG, and from a mean of 69.3 (SD
62.3) to 20.4 cm2 (SD 28.4) in the NCG (p < .001 for both
groups). Overall, there was no signiﬁcant difference in er-
ythema reduction between the CG and NCG (p ¼ .610).
D-dimer, which was elevated in 59 (81%) patients at
baseline (CG 1.1 mg/mL, SD 1.0; NCG 1.2 mg/mL, SD 0.9)
signiﬁcantly decreased irrespective of group afﬁliation
(p < .001 for both groups), reaching normal values in 39
(53%) patients at day 21 (CG 0.6, SD 0.5; NCG 0.5, SD 0.5;
p ¼ .520).
The mean physical score signiﬁcantly improved from
baseline to day 21 in both groups (CG: from 41.8 [SD 8.1] to
45.1 [SD. 8.0]; NCG: from 39.5 [SD 10.2] to 42.1 [SD 10];
p ¼ .006 for both groups) without a trend in favor of either
group (p ¼ .760). The mean baseline mental score was 47.7
(SD 11.1) in the CG and 50.8 (SD 10) in the NCG. The
respective values at day 21 were 46.4 (SD 9.3) in the CG and
Figure 4. Secondary endpoint thrombus length over time in pa-
tients receiving compression (d) or no compression (——). Note.
CG ¼ compression group; NCG ¼ no compression group.
Figure 2. Primary endpoint pain (visual analog scale [VAS]) over time
in patients receiving compression (d) or no compression (——).
Note. CG ¼ compression group; NCG ¼ no compression group.
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in the mental score for both groups during the observation
period (p ¼ .840).
Safety outcomes. No patient developed DVT or HIT.
DISCUSSION
The present study is, to the authors’ knowledge, the ﬁrst
randomized controlled trial in which the therapeutic efﬁ-
cacy of compression stockings (23e32 mmHg) on isolated
SVTof the legs has been compared with no compression. AnFigure 3. Primary endpoint pain (Lowenberg test) over time in
patients receiving compression (d) or no compression (——).
Note. CG ¼ compression group; NCG ¼ no compression group.observation period of 21 days was chosen to match the
duration of treatment that was common in the department
in which the study was conducted. After 3 weeks treatment
there was no statistically signiﬁcant difference between
compression and no compression in all tested outcomes.
Therefore, the null hypothesis had to be rejected in favor of
the alternative hypothesis of the given level of signiﬁcance
(power 80%, a ¼ .05).
A steady and highly signiﬁcant decrease in pain, ery-
thema, and thrombus length, as well as signiﬁcant
improvement of QoL within 3 weeks, irrespective of wear-
ing or not wearing compression stockings, was observed.
This can be attributed, in part, to the natural disease pro-
cess, and in part to the anti-inﬂammatory effect of NSAIDs
and LMWH, which have been shown to signiﬁcantly atten-
uate lipopolysaccharide-induced activation of human
mononuclear cells.14 The authors’ conclude that there is no
beneﬁt to wearing compression stockings for a prolonged
period of time in addition to taking LMWH and NSAIDs,
according to the equivalent outcome after 3 weeks in both
treatment groups for all clinical signs investigated. On the
contrary, up to day 7 compression stockings induced a
signiﬁcantly faster thrombus regression.
Leg compression has long been considered the basic
treatment for SVT as everyday experience has shown that
patients recover much faster with compression treatment,
yet there are no randomized trials demonstrating its
effectiveness.1 Only one uncontrolled trial addressed the
effect of compression on SVT without any additional sys-
temic drugs.10 After 2 weeks, clinical improvement was
reported in 93%, and CUS revealed partial or complete
thrombus regression in 81% of patients. However, no
detailed data on thrombus length before and after treat-
ment were recorded. In addition, favorable CUS results
470 K. Boehler et al.might have been biased by incision and clot extrusion
performed in 32% of patients. As no control group was
included, clinical improvement might be attributable, at
least in part, to spontaneous regression of the disease. A
further subject of discussion is that ﬁxed compression
bandages exerting higher pressures might be more effective
than compression stockings, which were used in the present
study.
The hemodynamic effects of compression therapy
depend on the exerted pressure, the stiffness of the device,
and on the body position.15 In the supine position, pres-
sures of 10e20 mmHg effectively increase blood ﬂow ve-
locity by narrowing of the leg veins.16 In the upright
position, a local pressure of >40 mmHg must be obtained
for diameter reduction of the leg veins.17,18 This can only be
achieved by strongly applied inelastic material, but not by
compression stockings. Another peculiar ﬁnding, that
compression narrows deep veins even more than superﬁcial
varices, further suggests that much higher pressures than
those exerted by compression stockings might be necessary
to effectively inﬂuence SVT in superﬁcial varices.19
Conversely, elastic stockings and high-pressure bandages
were found to be nearly equally effective regarding reduc-
tion of soft tissue edema, and Arpaia et al. demonstrated
that signiﬁcantly more venous segments recanalize when
compression stockings are applied immediately at the
diagnosis of DVT compared with 2 weeks later.20,21 The
observation in the present study that clots were resorbed
signiﬁcantly faster in the CG during the ﬁrst week of
treatment conﬁrms these ﬁndings and argues in favor of
compression treatment early in SVT. However, from the
patients’ perspective, compression treatment should ﬁrst of
all reduce pain associated with SVT. Whereas in this study
compression stockings failed to alleviate pain at any
particular time of the observation period, Partsch et al.
clearly demonstrated that within the ﬁrst 2 days of treat-
ment of DVT elastic stockings reduced pain and swelling
nearly as effectively as inelastic bandages.22 It can be
speculated that this might be owing to the fact that
compression stockings were worn during day and night, and
that the hemodynamic effect exerted in the supine position
accounted for the signiﬁcant pain reduction in this trial. A
possible explanation for this discrepancy could also be that
in the study of Partsch et al. the results concern the com-
bination compression plus walking versus no compression
and bed rest.22 It is unknown to what extent the relief of
pain was due to the compression or to the walking.
Although there are no reliable data on the effect of
compression stockings on SVT, trials dealing with
compression following foam sclerotherapy and GSV surgery
allow for a deeper insight into the pressure levels required
to reduce thrombosis, inﬂammation, and pain affecting
superﬁcial veins. Lugli et al. demonstrated that a signiﬁ-
cantly lower pain level can be achieved after endovenous
laser ablation by using an eccentric compression device in
addition to compression stockings.23 In an even more
elaborate study, Mosti et al. showed that ﬁxed eccentric
compression pads with compression stockings on top exertan interface pressure of at least 30 mmHg, which reduced
pain more effectively than plain adhesive bandages or
compression stockings.24 That the use of compression
stockings has been overestimated in the treatment of
varicose vein diseases is also evident from the fact that
compression stockings applied after GSV stripping or foam
sclerotherapy had no additional beneﬁt in terms of reduc-
tion of pain and edema when compared with no
compression.25,26 Likewise, patients’ satisfaction scores af-
ter sclerotherapy of telangiectasia and reticular veins were
the same with or without compression.27
According to the results of the present trial, which are
supported by coherent data from the literature, it is not
justiﬁed to recommend compression stockings in addition
to LMWH and NSAIDs for prolonged time periods, but they
might have beneﬁcial effects early in the disease process.
This raises the question of whether treatment with ﬁrm
elastic bandages for 1 week would be equally or more
effective than compression stockings. In particular, for
elderly and disabled patients who need homecare help with
compression stockings, short treatment periods are ad-
vantageous. In addition, the discomfort of wearing stock-
ings for a prolonged period of time, especially during
summer, can be avoided and costs saved.
The limitations of this study are a possible modiﬁcation
of the pain scores by the unrestricted intake of painkillers,
which was left to the patients’ needs. This might account, at
least in part, for the concealment of perception of disease-
associated pain. The long recruitment phase highlights the
difﬁculty in enrolling eligible patients with isolated SVT. This
is why the study population is quite heterogeneous with
respect to severity of disease and why SVT of the saphenous
veins, as well as side branches, were included. However, this
heterogeneity corresponds to the real-life situation, making
the results highly generalizable. The limited sample size
precluded subgroup analysis of SVT involving the lower leg,
or SVT of the saphenous veins. Owing to an expectedly
higher efﬁcacy of compression stockings at calf level,
favorable treatment results in patients with SVT of the
lower leg might thus have been concealed. Finally, it is
practically impossible to assess compliance with wearing
compression stockings in the treatment group as one can
only rely on patients’ cooperation.CONCLUSION
It has been routine for years to treat patients with SVT of
the legs with compression stockings. According to the re-
sults of this study there is evidence that adding compres-
sion stockings for 3 weeks to LMWH and NSAIDs does not
bring signiﬁcant additional beneﬁt to patients with isolated
SVT without DVT with respect to reduction of pain,
thrombus length, and erythema, as well as decrease of D-
dimer and QoL improvement. However, nothing can be said
about compression alone compared with medical therapy.
But early treatment with compression stockings might be
advantageous regarding thrombus regression. In the light of
this ﬁnding, controlled trials are required to assess if
European Journal of Vascular and Endovascular Surgery Volume 48 Issue 4 p. 465e471 October/2014 471compression for only 1 week and other devices like ban-
dages, Velcro devices, or eccentric compression pads top-
ped by compression stockings would be cheaper and more
efﬁcient in the treatment of isolated SVT. The results of the
present study also indicate that clinical signs and complaints
associated with isolated SVT are self-limited independently
of whether or not compression stockings are worn.
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